{"protocolSection":{"identificationModule":{"nctId":"NCT00698763","orgStudyIdInfo":{"id":"3001088"},"organization":{"fullName":"Orion Corporation, Orion Pharma","class":"INDUSTRY"},"briefTitle":"Effects of Oral Levosimendan on Ambulatory Electrocardiographic Variables","officialTitle":"Effects of Oral Levosimendan on Ambulatory Electrocardiographic Variables and Cerebrovascular Reactivity in Patients With Recent Stroke or TIA.","acronym":"Electro"},"statusModule":{"statusVerifiedDate":"2009-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-08"},"primaryCompletionDateStruct":{"date":"2009-04","type":"ACTUAL"},"completionDateStruct":{"date":"2009-09","type":"ACTUAL"},"studyFirstSubmitDate":"2008-06-12","studyFirstSubmitQcDate":"2008-06-16","studyFirstPostDateStruct":{"date":"2008-06-17","type":"ESTIMATED"},"lastUpdateSubmitDate":"2009-11-23","lastUpdatePostDateStruct":{"date":"2009-11-25","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Juha Ellmen, Clinical Program Leader","oldOrganization":"Orion Pharma"},"leadSponsor":{"name":"Orion Corporation, Orion Pharma","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The primary objective is to explore the safety of low doses of oral levosimendan in patients with recent history of an ischaemic cerebrovascular event (stroke or TIA). The main focus will be on the evaluation of proarrhythmic potential of the different dose regimens.","detailedDescription":"This is a prospective, multicentre, phase II, randomized, double-blind, placebo-controlled 2-arm parallel group study with 5 escalating dose-levels of oral levosimendan, each given for 13-18 days. The study population will be randomly allocated either to the levosimendan group or to the placebo group. The double-blind phase with either placebo or levosimendan is preceded by a 13-day long single-blind treatment with placebo (placebo run-in). The study consists of 9 visits (screening visit, 7 visits during the treatment period and an end-of-study visit). Each subject will be on study treatment (including placebo run-in) for 78-108 days and the duration of the study for each subject, including the screening and the end of study visit, is approximately 17 weeks."},"conditionsModule":{"conditions":["Transient Ischemic Attack","Stroke"],"keywords":["An ischaemic cerebrovascular event (stroke or TIA)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":32,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"A","type":"EXPERIMENTAL","description":"Levosimendan","interventionNames":["Drug: Levosimendan"]},{"label":"B","type":"PLACEBO_COMPARATOR","description":"Placebo","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Levosimendan","description":"from 0.125 mg to 2 mg in escalating doses","armGroupLabels":["A"]},{"type":"DRUG","name":"Placebo","description":"Placebo capsules are identical in appearance to active capsules","armGroupLabels":["B"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"24-h Holter reporting","timeFrame":"every 2 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female patients 50 to 80 years of age with ischaemic stroke or TIA within 1 to 9 months before the screening visit.\n\nExclusion Criteria:\n\n* Stroke or TIA due to cardiac embolism, vasculitis or arterial dissection\n* Severe hemiparesis or dysphasia, haemodynamically significant uncorrected valve disease or hypertrophic cardiomyopathy or restrictive cardiomyopathy, any acute coronary event or angioplasty or any other major surgery within 1 month, any major surgery during the planned study period\n* History of life-threatening ventricular arrhythmia within 3 months.\n* History of Torsades de Pointes (TdP) or family history of long QT-syndrome\n* Heart rate (HR) \\< 50 or \\> 100 bpm.\n* Systolic blood pressure (SBP) \\< 100 mmHg or \\> 180 mmHg, or diastolic blood pressure (DBP) \\> 100 mmHg.\n* Ventricular tachycardia.\n* Episode of atrial fibrillation or atrial flutter lasting \\> 60 seconds.\n* Second or third degree atrioventricular (AV) block.\n* Potassium (K) \\< 3.7 mmol/l or \\> 5.5 mmol/l.\n* Creatinine \\> 170 µmol/l or on dialysis.\n* Blood haemoglobin \\<10 g/dl; clinically significant hepatic impairment.","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Irja Korpela","affiliation":"Orion Corporation, Orion Pharma","role":"STUDY_DIRECTOR"},{"name":"Risto O. Roine, M.D., Ph.D.","affiliation":"Turku University Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Helsinki University Hospital (HUCH)","city":"Helsinki","country":"Finland","geoPoint":{"lat":60.16952,"lon":24.93545}},{"facility":"Turku University Hospital (TYKS)","city":"Turku","zip":"20521","country":"Finland","geoPoint":{"lat":60.45148,"lon":22.26869}},{"facility":"Heidelberg University Clinic","city":"Heidelberg","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"Debrecen University","city":"Debrecen","country":"Hungary","geoPoint":{"lat":47.53333,"lon":21.63333}},{"facility":"Sahlgrenska University Hospital, Dept of Neurology","city":"Gothenburg","zip":"413 45","country":"Sweden","geoPoint":{"lat":57.70716,"lon":11.96679}},{"facility":"University Hospital, Neurologmottagningen","city":"Linköping","zip":"581 85","country":"Sweden","geoPoint":{"lat":58.41086,"lon":15.62157}},{"facility":"Umeå University Hospital, Strokecenter NVS","city":"Umeå","zip":"901 85","country":"Sweden","geoPoint":{"lat":63.82842,"lon":20.25972}}]},"referencesModule":{"references":[{"pmid":"26082815","type":"DERIVED","citation":"Kivikko M, Kuoppamaki M, Soinne L, Sundberg S, Pohjanjousi P, Ellmen J, Roine RO. Oral Levosimendan Increases Cerebral Blood Flow Velocities in Patients with a History of Stroke or Transient Ischemic Attack: A Pilot Safety Study. Curr Ther Res Clin Exp. 2015 Jan 29;77:46-51. doi: 10.1016/j.curtheres.2015.01.001. eCollection 2015 Dec."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000002546","term":"Ischemic Attack, Transient"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000002545","term":"Brain Ischemia"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M5485","name":"Ischemic Attack, Transient","asFound":"Transient Ischemic Attack","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077464","term":"Simendan"}],"ancestors":[{"id":"D000002316","term":"Cardiotonic Agents"},{"id":"D000014665","term":"Vasodilator Agents"},{"id":"D000058987","term":"Phosphodiesterase 3 Inhibitors"},{"id":"D000010726","term":"Phosphodiesterase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M1805","name":"Simendan","asFound":"Microbial","relevance":"HIGH"},{"id":"M5262","name":"Cardiotonic Agents","relevance":"LOW"},{"id":"M17102","name":"Vasodilator Agents","relevance":"LOW"},{"id":"M29023","name":"Phosphodiesterase 3 Inhibitors","relevance":"LOW"},{"id":"M13319","name":"Phosphodiesterase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"CaAg","name":"Cardiotonic Agents"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}